患有心力衰竭的患者的纤维素1和2水平:比较不同心力衰竭阶段,探索急性恶化期间的时间变化
Burcu Cihan Talay1, Emrullah Kızıltunç2, Canan Yılmaz3
1Department of Cardiology, Bilecik Bozüyük State Hospital, 11300 Bilecik, Turkey.
Reviews in cardiovascular medicine
|March 3, 2025
概括
血清纤维素1水平随心力衰竭 (HF) 阶段的变化而变化,并与像NT-proBNP这样的预后标志物相关联. 纤维素2水平在HF患者中没有显示出显著的变化或相关性.
科学领域:
- 生物化学 生物化学
- 心脏病学 心脏病学
- 细胞外矩阵生物学 细胞外矩阵生物学
背景情况:
- 细胞外矩阵 (ECM) 改造在心力衰竭 (HF) 病原发生过程中至关重要.
- 纤维素1和纤维素2是ECM糖蛋白,与疾病进展有关.
- 了解纤维素在HF预后中的作用对于开发新的治疗策略至关重要.
研究的目的:
- 为了比较心力衰竭 (HF) 不同阶段的血清纤维素1和纤维素2水平.
- 研究纤维素水平与已确定的HF预后因素之间的关系,包括左心室喷射分数 (LVEF) 和NT-proBNP.
- 分析非补偿性HF住院期间纤维素水平的时间变化.
主要方法:
- 患者根据LVEF (减轻vs非减轻) 和临床状态 (A-BvsC-D阶段) 将患者分为HF阶段.
- 血清纤维素1,纤维素2和NT-proBNP水平在对照组和HF患者的入院,出院和1个月的随访时被测量.
- 进行了统计分析,以比较群体之间的水平,并评估与临床参数的相关性.
主要成果:
- 与对照组相比,HF患者的血清纤维素1和NT-proBNP水平显著升高.
- 纤维素1和NT-proBNP水平从入院到出院显著下降,并在1个月内保持稳定.
- 血清纤维素1与NT-proBNP正相关,与LVEF负相关;纤维素2没有显著的相关性.
结论:
- 血清纤维素1水平不同于HF阶段,并表现出与NT-proBNP类似的动态变化.
- 纤维素1可以作为HF进展和严重程度的潜在生物标志物.
- 在这项研究中,纤维素2与HF阶段或预后因素没有显著的关联.
相关概念视频
Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
Imbalances in Cardiac Output
1.3K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.3K
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
79
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
79
Heart Failure Drugs: β-Blockers
306
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
306
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
363
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
363
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
41
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
41


